Compare UNH & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | NVO |
|---|---|---|
| Founded | 1977 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.5B | 172.5B |
| IPO Year | 2010 | N/A |
| Metric | UNH | NVO |
|---|---|---|
| Price | $286.77 | $38.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 11 |
| Target Price | ★ $387.79 | $51.00 |
| AVG Volume (30 Days) | 6.1M | ★ 18.5M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 3.07% | ★ 3.20% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.23 | N/A |
| Revenue | ★ $447,567,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.31 | $3.30 |
| P/E Ratio | $21.69 | ★ $13.60 |
| Revenue Growth | ★ 11.81 | N/A |
| 52 Week Low | $234.60 | $35.85 |
| 52 Week High | $606.36 | $81.44 |
| Indicator | UNH | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 34.84 |
| Support Level | $269.68 | $35.85 |
| Resistance Level | $294.66 | $39.88 |
| Average True Range (ATR) | 7.02 | 0.89 |
| MACD | 1.00 | 0.48 |
| Stochastic Oscillator | 56.79 | 64.55 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.